Chen Huajian, Ji Jingsen, Zhang Li, Chen Taoliang, Zhang Yuxuan, Zhang Fabing, Wang Jihui, Ke Yiquan
The National Key Clinical Specialty, The Engineering Technology Research Center of Education Ministry of China, Guangdong Provincial Key Laboratory on Brain Function Repair and Regeneration, Department of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J Control Release. 2023 Oct;362:479-488. doi: 10.1016/j.jconrel.2023.08.020. Epub 2023 Sep 8.
Surgical resection of glioblastoma (GBM) causes brain inflammation that activates and recruits neutrophils (NEs) to residual GBM tissues. NE-based drug delivery using inflammatory chemotaxis is promising for the post-surgical treatment of residual GBM, but its clinical application is limited by the short life span of NEs and lack of in vitro propagation methods. HL60 cells are a type of infinitely multiplying tumor cells that can be induced to differentiate into NE-like cells. We developed a novel NE-like membrane system (NM-PD) by coating NE-like membranes on the surface of poly (lactide-co-glycolide)-poly(ethylene glycol) (PLGA-PEG)-based doxorubicin (DOX)-loaded core (PLGA-PEG-DOX, PD) for post-surgical residual GBM treatment. Cell adhesion proteins were detected on NE-like membranes and endowed NM-PDs with inflammatory chemotaxis similar to mature NEs. The resulting NM-PD shows excellent inflamed in vitro blood-brain barrier (BBB) permeability and anti-proliferative effects on GBM cells. In our intracranial GBM resection model, NM-PD exhibited superior inflammatory chemotaxis and targeted residual GBM cells, thus remarkably improving antitumor capability and prolonging the survival time of the mice. These data suggest that NM-PD, which has sufficient sources and is easy to prepare, can efficiently suppress post-surgical residual GBM and holds potential for clinical transformation in GBM post-surgical adjuvant therapy.
胶质母细胞瘤(GBM)的手术切除会引发脑部炎症,激活并招募中性粒细胞(NE)至残留的GBM组织。利用炎症趋化作用进行基于NE的药物递送,对于GBM术后残留组织的治疗具有广阔前景,但其临床应用受限于NE的短寿命以及缺乏体外增殖方法。HL60细胞是一种可无限增殖的肿瘤细胞,能够被诱导分化为类NE细胞。我们通过在聚(丙交酯-乙交酯)-聚(乙二醇)(PLGA-PEG)基负载阿霉素(DOX)的核(PLGA-PEG-DOX,PD)表面包覆类NE膜,开发了一种新型类NE膜系统(NM-PD),用于术后残留GBM的治疗。在类NE膜上检测到细胞黏附蛋白,赋予NM-PD与成熟NE相似的炎症趋化作用。所得的NM-PD在体外显示出优异的炎症性血脑屏障(BBB)通透性以及对GBM细胞的抗增殖作用。在我们的颅内GBM切除模型中,NM-PD表现出卓越的炎症趋化作用并靶向残留的GBM细胞,从而显著提高抗肿瘤能力并延长小鼠的生存时间。这些数据表明,来源充足且易于制备的NM-PD能够有效抑制术后残留GBM,在GBM术后辅助治疗中具有临床转化潜力。